Global Trastuzumab Injection Market Growth 2024-2030

Global Trastuzumab Injection Market Growth 2024-2030

Trastuzumab is a targeted cancer drug and is also known by other names such as Herceptin, Herzuma and Ontruzant. It is a treatment for early and advanced breast cancer, advanced stomach cancer and cancer of where the food pipe joins your stomach (gastro oesophageal junction). Trastuzumab injection products are used with other medications or after other medications have been used to treat a certain type of breast cancer that has spread to other parts of the body. Trastuzumab injection products are also used during and after treatment with other medications to decrease the chance that a certain type of breast cancer will return. Trastuzumab injection products are also used with other medications to treat certain types of stomach cancer that have spread to other parts of the body. Trastuzumab is in a class of medications called monoclonal antibodies. It works by stopping the growth of cancer cells.

The global Trastuzumab Injection market size is projected to grow from US$ 758.1 million in 2023 to US$ 1102.7 million in 2030; it is expected to grow at a CAGR of 5.5% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Trastuzumab Injection Industry Forecast” looks at past sales and reviews total world Trastuzumab Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Trastuzumab Injection sales for 2024 through 2030. With Trastuzumab Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Trastuzumab Injection industry.

This Insight Report provides a comprehensive analysis of the global Trastuzumab Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Trastuzumab Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Trastuzumab Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Trastuzumab Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Trastuzumab Injection.

United States market for Trastuzumab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Trastuzumab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Trastuzumab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Trastuzumab Injection players cover Pfizer, Roche, Celltrion, Amgen and Samsung Bioepsis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Trastuzumab Injection market by product type, application, key manufacturers and key regions and countries.

Segmentation by type
60 mg
150 mg
440 mg
Others

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Roche
Celltrion
Amgen
Samsung Bioepsis
Mylan
Glenmark
AstraZeneca
Remegen Co., Ltd.
Hisun Biopharmaceutical
Shanghai Henlius Biotech

Key Questions Addressed in this Report

What is the 10-year outlook for the global Trastuzumab Injection market?

What factors are driving Trastuzumab Injection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Trastuzumab Injection market opportunities vary by end market size?

How does Trastuzumab Injection break out type, application?

Please note: The report will take approximately 2 business days to prepare and deliver.